Revolution Medicines (NASDAQ:RVMD – Get Free Report) and Tevogen Bio (NASDAQ:TVGN – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.
Profitability
This table compares Revolution Medicines and Tevogen Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Revolution Medicines | N/A | -34.57% | -30.71% |
| Tevogen Bio | N/A | -387.78% | 434.75% |
Institutional and Insider Ownership
94.3% of Revolution Medicines shares are held by institutional investors. 8.0% of Revolution Medicines shares are held by company insiders. Comparatively, 56.6% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Revolution Medicines | 0 | 0 | 10 | 1 | 3.09 |
| Tevogen Bio | 0 | 0 | 1 | 0 | 3.00 |
Revolution Medicines presently has a consensus target price of $54.00, indicating a potential upside of 14.29%. Tevogen Bio has a consensus target price of $4.20, indicating a potential upside of 64.06%. Given Tevogen Bio’s higher probable upside, analysts plainly believe Tevogen Bio is more favorable than Revolution Medicines.
Volatility & Risk
Revolution Medicines has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500. Comparatively, Tevogen Bio has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.
Earnings & Valuation
This table compares Revolution Medicines and Tevogen Bio”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Revolution Medicines | $11.58 million | 681.58 | -$436.37 million | ($3.64) | -12.98 |
| Tevogen Bio | N/A | N/A | -$70,000.00 | N/A | N/A |
Tevogen Bio has lower revenue, but higher earnings than Revolution Medicines.
Summary
Revolution Medicines beats Tevogen Bio on 7 of the 11 factors compared between the two stocks.
About Revolution Medicines
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company’s RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
About Tevogen Bio
Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.
